Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer

  • Seagen Inc (NASDAQ:SGENannounced topline results from phase 2 MOUNTAINEER trial investigating Tukysa (tucatinib) in combination with trastuzumab in previously treated HER2-positive metastatic colorectal cancer (mCRC) patients. 
  • Trastuzumab is sold under the name Herceptin by Genentech, a unit of Roche Holdings AG (OTC:RHHBY).
  • Data from this trial will form the basis of a planned supplemental marketing application to the FDA under the FDA's Accelerated Approval Program. 
  • Also Read: Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence.
  • Merck & Co Inc (NYSE:MRK) is commercializing Tukysa in regions outside the U.S., Canada, and Europe.
  • Results showed a 38.1% confirmed objective response rate (cORR).
  • The median duration of response (DoR) was 12.4 months. The combination of tucatinib and trastuzumab was generally well-tolerated. The most common adverse treatment-emergent events were diarrhea, fatigue, nausea, and infusion-related reaction, primarily low-grade.
  • Price Action: SGEN shares are up 0.82% at $140.79 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.